Navigation Links
DURECT Announces Closing of Public Offering of Common Stock
Date:11/13/2013

CUPERTINO, Calif., Nov. 13, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 7,142,858 shares of its common stock, offered at a price of $1.40 per share to the public.  All of the shares in the offering were sold by DURECT.  DURECT granted the underwriters a 30-day option to purchase up to an aggregate of 1,071,429 additional shares and the underwriters exercised this option in full prior to the closing.  As a result, DURECT sold a total of 8,214,287 shares of its common stock in this offering.  The gross proceeds to DURECT from this offering were approximately $11.5 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by DURECT. 

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

Stifel acted as sole book-running manager for the offering and Janney Montgomery Scott acted as co-manager. 

Felix Theeuwes, DURECT's Chairman and Chief Scientific Officer, purchased 714,285 shares of the 8,214,287 shares of common stock in the offering, at the public offering price, for an aggregate purchase price of approximately $1.0 million.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective.  A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov.  When available, copies of the final prospectus supplement may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.

NOTE: POSIDUR, SABER®, ORADUR®, TRANSDUR® and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR, TRANSDUR-Sufentanil, ORADUR-Methylphenidate and Relday are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Proposed Public Offering of Common Stock
2. DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs
3. DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call
4. DURECT Announces Changes to its Board of Directors
5. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
6. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
7. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
8. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
9. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
10. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
11. DURECT to Participate in Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ABU DHABI , UAE, May 23, 2016 ... the importance of Precision Medicine and the role ...     The First International ... under the distinguished patronage and presence of Sheikh ... Development. The conference focused in Precision Medicine, which helps provide ...
(Date:5/23/2016)... FRANCISCO , May 23, 2016 ... to reach USD 5.0 billion by 2022, according to ... increasing generation of medical waste coupled with the lack ... industry is expected to drive the demand for reprocessed ... these devices as compared to that of the original ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
Breaking Medicine Technology:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... The Society ... MSW, has decided to move on from that role. , “No one in Washington ... did Phyllis Greenberger,” said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... to residents of Westchester County for over 24 years, recently hosted its sixth ... members joined HOW for two remembrance ceremonies, each concluding with the release of ...
(Date:5/23/2016)... , ... May 23, 2016 , ... VitreosHealth is presenting ... 10, 2016 from 11:00 AM – 12:00 PM ET. To register, click ... start a proactive outreach program built on Big Data with a new predictive and ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... information management systems (LIMS), electronic laboratory notebook systems (ELNS) and related systems is ... manual data management consumes a significant amount of lab technician time and introduces ...
(Date:5/23/2016)... ... May 23, 2016 , ... SPH ... as Chief Medical Officer. Dr. O’Connor’s deep expertise in medicine and HIT will ... services teams who deliver best-in-class solutions and transformative technologies for provider, payer, and ...
Breaking Medicine News(10 mins):